J&J: TREMFYA Data Show an Overall Clinical Response Rate of ~80% in Phase 2b in Ulcerative Colitis

 

• Previously reported results from QUASAR Induction Study 1 showed clinical response was achieved by approximately 60 percent of patients at week 12
• Study results presented at 2022 American College of Gastroenterology Annual Meeting showed that continued treatment with subcutaneous TREMFYA allowed a mean of 52.1 percent of IV TREMFYA week 12 clinical nonresponders to achieve clinical response at week 24

https://www.biospace.com/article/releases/new-tremfya-guselkumab-data-show-an-overall-clinical-response-rate-of-approximately-80-percent-in-a-phase-2b-induction-study-of-adults-with-moderately-to-severely-active-ulcerative-colitis/